WE RESEARCH. WE DEVELOP. WE FIGHT.

FOR A WORLD WITHOUT TYPE 1 DIABETES.

 

© Helmholtz Zentrum München / Jörg Simanowski (Markenfotografie)

The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was launched in 2015 and brings together several academic research institutions and hospitals in Europe. GPPAD aims to establish an international infrastructure for studies dedicated to preventing the development of type 1 diabetes.

 

Read more about our studies here

 

We conduct studies in Belgium, Germany, the UK, Poland, and Sweden for the early detection of an increased genetic risk of type 1 diabetes and prevention of disease development.

Read more about study participation in Germany:

Increased risk of type 1 diabetes: Early detection

Freder1k: early detection for newborns up to 7 days old

 

New study on the prevention of type 1 diabetes autoimmunity. 

SINT1A: for newborns up to 6 weeks old with an increased risk of type 1 diabetes.

 

Prevention study for infants with an increased risk

POInT: for infants between four and seven months old

Participation no longer possible

 

More than

Infants were tested for increased risk of type 1 diabetes in the Freder1k study

 

More than

children are taking part in our POInT prevention study

 

 

GPPAD locations in five countries are making every effort to achieve a world without type 1 diabetes

Secured By miniOrange